Together, FOXA1 and GRHL2 induce the expression and activity of LYPD3, a Ly6 receptor family member, as well as its ligand AGR2, in mouse models of endocrine resistant breast cancer, as well as patient tumors that progressed on endocrine therapy. Here, LYPD3 is linked to breast carcinoma.